Tag: melanoma

1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level: 1 (Excellent) Immune-related adverse events (irAEs) occur frequently in patients treated with immune checkpoint inhibitors (ICIs). Retrospective studies and small prospective studies have reported an association between irAEs and...
1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level: 1 (Excellent) Immune-related adverse events (irAEs) occur frequently in patients treated with immune checkpoint inhibitors (ICIs). Retrospective studies and small prospective studies have reported an association between irAEs and...
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level:...
The ideal surgical excision margin for patients with thick (>2 mm) localized cutaneous melanomas is unclear, where the risk of recurrence must be weighed against excess morbidity resulting from larger skin defects with wide excision. In this randomized controlled trial, 936 clinically staged patients were recruited and randomly assigned...
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial The ideal surgical excision margin for patients with thick (>2 mm) localized cutaneous melanomas is unclear, where the risk of recurrence must be weighed against excess morbidity resulting from...
1. A woman developed anti-AMPA receptor encephalitis in the setting of metastatic melanoma. 2. Following a short delay, she responded well to vemurafenib and cobimetinib. At the end of the study at 9 months, she remained in complete remission. Evidence Rating Level: 4 (below average)           Study Rundown: Anti-AMPA receptor encephalitis can occur...
1. α-melanocyote stimulating hormone (α -MSH) and its analogs can bind tightly to the melanocortin-1 receptor (MC1R), a G protein-coupled receptor that is overexpressed in melanoma cells. 2. Radionuclide and fluorescent MSH probes demonstrate MC1R-specific targeting properties in murine and human melanoma cells and tumors. Evidence Rating Level: 2 Study Rundown:...
Immune checkpoint inhibitors have shown significant antitumor activity in melanoma. However, previous randomized trials have excluded patients with untreated brain metastases due to concerns regarding central nervous system penetration and poor prognosis. In this phase II trial, 23 patients with stage IV melanoma and at least one 5-20 mm...
Programmed death-1 (PD-1) inhibitors have shown efficacy in the treatment of melanoma. Pre-existing CD8+ T-cell infiltrate and interferon (IFN) gene signature has been shown to correlate with response to PD-1 blockade. As such, the receipt of combination therapy with interferon (IFN) may enhance anti-tumor effects. In this open-label phase...
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty Many studies have suggested that aspirin may be effective in the prevention of venous thromboembolism (VTE) after total hip or total knee arthroplasty. However, few randomized controlled trials comparing aspirin with direct oral anticoagulants are available. In this multicenter,...